Upload
others
View
6
Download
0
Embed Size (px)
Citation preview
Examples of founding and evolving leading LifeScience companies
November 2016
2 IDEAHUB TRILAGO| November 2016 |
Peter Pohl
Born: in Salzburg
Love: my wife and my two children (age 9&7)
Education: Business Adminstration
Serial entrepreneur
Passion: Founding of companies, growth of
companies, leadership, consultancy
Place of Living: The Bodensee
3 IDEAHUB TRILAGO| November 2016 |
The beginning
4 IDEAHUB TRILAGO| November 2016 |
Foto Hinterhof Fritz-Arnold-Strasse
5 IDEAHUB TRILAGO| November 2016 |
GATC Headquarter Konstanz
6 IDEAHUB TRILAGO| November 2016 |
GATC Biotech – Innovation management throughout the years
New technologies allow better insights and deeper understanding of scientific requirements.
World’s first non-radioactive sequencing technology
Today
1st NGS service provider
Multiplatform (PacBio + HiSeq + MiSeq)
Realisation of personalised medicine
GATC-BöxleTM
1st 24h sequencing service
GATCLIQUIDTM
7 IDEAHUB TRILAGO| November 2016 |
Online platform
1 2 3 4 5 6 7
All tubes/plates carry barcode labels
Efficient logistic solutions
Automated production processes
Sequencing, assembly & analysis
Data delivery via secured myGATC account
Customer Hotline; NextGen projects supervised by project management
Our service workflow enables high-quality research
8 IDEAHUB TRILAGO| November 2016 |
Production: The power horses at GATC
European Custom Sequencing Center, Cologne, Germany
Genome and Diagnostic Centre, Constance, Germany
Fastest Sanger sequencing service in Europe
ISO 17025 accredited Swift logistics Overnight service
~2.500.000 samples p.a.
Next-generation sequencing on all prevalent technologies
INVIEW – standardised NGS ISO 17025 / ISO 13485 Certified Service Provider of Illumina and PacBio
~50.000 samples p.a.
9 IDEAHUB TRILAGO| November 2016 |
We have subsidiaries, labs and sales offices in…
… Germany (incl. Labs)
… Great Britain
… France
… Sweden
… and customers in over 30 countries
European wide sales and production
structure
10 IDEAHUB TRILAGO| November 2016 |
Product Portfolio: GATC Sequencing Solutions overview
Pre-Sequencing
LIFE TECHNOLOGIES Pacific Bioscience
Illumina
HUMAN EXOME AMPLICON TRANSCRIPTOME EPIGENOME MODIFICATION ANALYSIS DE NOVO GENOME MICROBIOME
Flexibility in services, delivery times and batch size NightXpressTM
Tubes or 96-well format
Library
Sequencing
Bio-IT
Sanger sequencing Next Generation Sequencing
11 IDEAHUB TRILAGO| November 2016 |
Uniqueness of GATC Biotech
GATC is the No. 1 Service Provider of DNA and RNA sequencing in Europe since 25 years
Family owned business in the molecular diagnostics area
Experience and loyalty of Management
Excellent network in the academic and medical space with more then 10.000 customers
High reputation and strong, well-known brand
GATC runs a profitable core business with strong upside opportunities in molecular diagnostics
First-Mover experience (new technologies, LifeCodexx, Liquid Biopsy)
Successful entry in the diagnostics market with LifeCodexx
Scaling and optimizing processes in the molecular biology area
Patents and proprietary processes & algorithms (GATC-LIMS, PraenaTest, PraenaBoxx)
Accreditated processes with ISO 17025, ISO 13485, ISO 9001; Certified Service Provider of Agilent, Illumina and Pacific Biosciences; potential CAP/CLIA accreditation
GATCLIQUID The Liquid Biopsy Service Line of GATC
13 IDEAHUB TRILAGO| November 2016 |
Limitations of tissue biopsy
Biopsy is invasive May not be feasible based on patient condition or tumour accessibility
Impractical for periodic monitoring for progression recurrence
Biopsy tissue is often very limited Greater demand due to molecular profiling
Surgery is costly
Example Cancer: heterogeneous disease Molecular properties differ within tumours
Therapy causes changes in tumour cells
14 IDEAHUB TRILAGO| November 2016 |
The principle of liquid biopsy
15 IDEAHUB TRILAGO| November 2016 |
Liquid Biopsy – The X-Ray of the 21st century
Liquid Biopsy is non-invasive – declining need for operations for diagnostic purpose
Body fluids are easier and less costly to collect compared to solid biopsies
Growing interest in research brings Liquid Biopsy in clinical environment
Liquid biopsies have the potential to replace traditional invasive diagnostics methods that are often ineffective or nearly impossible to perform. By improving the outcome for cancer patients, liquid biopsy can ultimately become the X-ray of the 21st century.
16 IDEAHUB TRILAGO| November 2016 |
GATCLIQUID: GATC’s research services for cancer research and diagnosis
Unbiased discovery
Exome sequencing of matched samples from tumour tissue, cell-free DNA and blood
ONCOEXOME
Targeted screening
Panel sequencing of clinically actionable mutations, including low frequency mutations
ONCOPANEL
Monitoring
Frequent detection of single driver mutations after treatment, such as surgery or therapy
ONCOTARGET
17 IDEAHUB TRILAGO| November 2016 |
GATCLIQUID services follows the cancer treatment timeline
Screening Diagnosis Follow-up Treatment
STAGING SURGERY | CHEMO | RADIATION RECUPERATION
Biopsy Imaging Tumour size Molecular stratification
Tumour removal Irradiance Medication
Monitoring
Diagnosis
Adjuvant treatment decision Companion diagnostics Measurement of therapeutic response Follow-up
GATCLIQUID ONCOEXOME
ONCOPANEL
ONCOTARGET
LifeCodexx© Establishing Market Leadership with Liquid Biopsy in Prenatal Diagnostics
19
Market Opportunity Non-invasive prenatal testing (NIPT) is the safest and most accurate option to test for genetic abnormalities during pregnancy
20
First NIPT to enter the European market when it was launched in August 2012 following clinical validation
Originally (at launch) focused on the detection of fetal trisomy T21; test capabilities have since been extended to detect T13, T18,
gonosomal aneuploides and multiple pregnancies
• Only NIPT in Europe for the detection of the indicators listed above that is performed in accordance with the In-Vitro Diagnostics Directive
98/79/EG of the European Union (requires both CE-marked analysis software and a full quality assurance system)
Utilizes Massively Parallel Sequencing (MPS), which is typically accepted as one of the best validated methods for NIPT
PrenaTest® NGS NIPT for detection of fetal trisomies T21, T13, T18 and more
Currently available in 35 countries across Europe, the Middle East and Asia
• Currently holds either the number one or two market position in all active territories
• Recently launched in Italy, Belgium, Serbia, Slovenia, Croatia, Macedonia, Montenegro,
Ukraine, Greece, Portugal with ongoing launches in Russia, India, Vietnam and Spain
Analysis includes the use of both LifeCodexx’ proprietary QuantYfeX® assay (for
quantification of fetal DNA at the beginning of the analysis) and PrenaTest®
DAP.plus analysis software (for bioinformatic analysis of the sequencing data)
Applied for reimbursement in Germany and Switzerland submitted in 2013 and in
Hungary in 2015; received statutory reimbursement in Switzerland in 2015 and
Germany and Hungary are pending
Initiated a Post Marketing Clinical Follow-Up (PMCF) study with the University of
Bonn in Germany; aim is to determine the birth outcome of ~2,000 patients - more
than 1,500 patients recruited to date
21 IDEAHUB TRILAGO| November 2016 |
Challenges during Founding & Evolving
Get the product
DBE / Services / PrenaTest
Get the investment
Own money
Customer
Public funds
Other people´s money („OPM“): VC / PE / Family Office / F&F
Get the right team
More important than product and money!!
Get the customer
…the only one that brings in money (if you want to earn money)
Get the grip
Think first… and then move, move, move
Move the bottlenecks
…or they will move you…
22 IDEAHUB TRILAGO| November 2016 |
Thank you!